Aki Prihti
Chief Executive Officer; M.Sc. (Econ. and BA)

Aki started as Aplagon’s CEO in February 2015. Aki is one of the founders of Inveni Capital, a life sciences focused venture capital fund, and serves as a board member in Herantis Pharma Oyj and Priaxon AG. Aki has been involved in setting up and developing, as well as fundraising for, several life science companies and has served as a board member among others in Onbone Oy and Medtentia International Oy. Aki has more than fifteen years of experience in life science growth companies, both in operational and board roles.
   
 
Riitta Lassila
Chief Scientific Officer, Co-founder; MD, PhD, Prof.

Riitta is co-founder and CSO of Aplagon. Riitta is Head of Coagulation Disorders in Helsinki University Hospital and Professor in Coagulation Disorders in Helsinki University. Riitta serves as CSO besides her primary clinical duty. Riitta has training in internal medicine and thrombosis and haemostasis research. She has supervised several theses in Helsinki University and authored over 2000 original or review articles or book chapters. She has served a steering committee member of EAHAD and EUHANET, a European haemophilia and allied disorders program, and an editor of Thrombosis Research. She has several advisory board memberships in pharmaceutical companies.
   
 
Sakari Lassila
Chairman of the Board, Co-founder; M.Sc. (Econ. and BA)

Sakari, co-founder of Aplagon, has 30 years of experience from international commercial banking, investment banking, corporate finance and investment company management where he has held senior positions at Union Bank of Finland (now part of Nordea), Citibank, Alfred Berg and Carnegie. Sakari is now managing director and co-owner of Indcrea Oy, an industrial investment company based in Finland.
   
 
Arja Kuittinen
Non-Executive Director; M.Sc. (Biol.), BBA

Arja has more than 25 years of management experience in life sciences industry including management positions in e.g. Quintiles and Hoechst Marion Roussel. Currently she is Chairman and non-executive director in several Finnish start-up companies. Arja served as Aplagon's CEO until January 2013.
   
 
Harry Holthöfer
Non-Executive Director; MD, PhD, Prof.

Harry brings a wealth of international experience in translational research in diabetes, cardiovascular and kidney diseases and also as an entrepreneur. Harry is Professor of Bioanalytical Sciences and Director and Chair of the Centre for BioAnalytical Sciences at Dublin City University and serves as Research Director at University of Helsinki, Finland, Adjunct Professor at University of Shenzhen, China and Visiting Professor at Southern Medical University, Guangzhou, China and University of Freiburg, Germany. Harry is also co-founder and CEO of three start-up biotech companies.
   
 
Kai Lindevall
Non-Executive Director, Co-founder; MD, PhD

Kai, co-founder of Aplagon and former President and CEO of Encorium Group, brings over twenty years of senior management and entrepreneurship experience in pharmaceutical, biotech and CRO industry. Kai was one of the founders of Remedium (a predecessor to Encorium) and Ipsat Therapies and has served as Medical Advisor to Farmos, Medical Director to Rhône-Poulenc Rorer and as Associate Director of Research at Wihuri Research Institute in Finland, where he led his own research group involved in thrombosis research.
   
 
Steven Myint
Non-Executive Director; MD, PhD

Steve is an advisor to the chairman of Singapore's Agency for Science and Technology, among other governmental organizations. He was the executive chairman of Green Signal Bio, one of India's largest independent vaccine manufacturers. Prior to that he was global Medical Director of GlaxoSmithKline (GSK) and Senior Vice-President for R&D/Chief Medical Officer at BTG International. He is actively involved in innovative biotech companies and co-founded Finland's largest accelerator fund. He is a Fellow or Member of several societies, including the Institute of Knowledge Transfer, the Royal College of Physicians and the Royal Society of Medicine.
   
 
Jim Phillips
Non-Executive Director; MD, MBA

Jim is CEO of Midatech Pharma plc, a nanomedicine based pharmaceutical development company listed on London stock exchange. Jim has a strong background in company leadership and business development, and is a physician by training. He founded Talisker Pharma in 2004, which was acquired by EUSA Pharma in 2006 and ultimately by Jazz Pharmaceuticals in 2012. Jim is currently a non-executive director of Herantis Pharma Oyj, Insense Ltd (a private spin-out from Unilever), and, until joining Midatech, was Chairman of Prosonix Limited. Jim initially held senior positions at Johnson & Johnson and Novartis Pharmaceuticals. At Novartis, he was a Board Director of the $1.3bn Arthritis, Bone, Gastrointestinal, Haematology and Infectious Diseases business unit and a member of the company’s Clinical Leadership Team.
   
About Us Products Publications Contact
     

Management

Aki Prihti
Chief Executive Officer

Riitta Lassila
Chief Scientific Officer


Board of Directors

Sakari Lassila
Chairman of the Board

Arja Kuittinen
Non-Executive Director

Harry Holthöfer
Non-Executive Director

Kai Lindevall
Non-Executive Director

Steven Myint
Non-Executive Director

Jim Phillips
Non-Executive Director



      © Aplagon Oy 2015